Shares closed at $82.28 on Tuesday, marking a second consecutive day of losses and finishing 6.38% below the 52-week high of $87.89.
The S&P 500 fell 0.49% and the Dow Jones slipped 0.05%, while competitors Abbott Laboratories rose 1.14%, Medtronic dropped 1.23%, and Stryker fell 2.30%.
Edwards Lifesciences underperformed some peers during a generally negative trading session, reflecting wider market volatility and investor caution across the sector.
After strong earnings, why is Edwards Lifesciences' stock falling?
With insiders selling millions in shares, is Edwards Lifesciences dangerously overvalued?
Has the heart device leader missed the boat on the booming PFA market?
Is Medtronic’s latest acquisition the start of a new medtech arms race?
Can premium medical devices survive the market's shift to cheaper surgical centers?
Could the new wave of weight-loss drugs disrupt the entire heart valve industry?